Duocarmycin analogs

Antibody-drug conjugates are designed to combine the specificity of antibodies directed against tumor-associated targets with potent cytotoxity. Upon internalization of the ADC, the antibody-bound c...

Drug Development for Rare Diseases

The economics of any industry relies on a large demand for a particular product; this applies to the pharmaceutical industry where efforts are focused on big and relatively straight-forward diseases...

Synthon Unveils Another ADC Facility

ADCs are a hot topic in drug development even though only two have been approved so far and one of those withdrawn. Regardless, Roche's (Genentech) T-DM1 is widely expected to gain approval in 2013 an...

Synthon enters into global license agreement with Amgen and Watson for biosimilar trastuzumab

Synthon announced that it has entered into a global license agreement with Amgen Inc. and Watson Pharmaceuticals, Inc. for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin®, whic...

Synthon Unveils ADC Facility as Data Show Promise for First Candidate

Following a wave of recent investment in ADC production, Synthon has opened an ADC manufacturing facility in Nijmegen, Netherlands, to help bring its first preclinical ADC program to clinical trials b...

Amgen, Synthon and Watson Pharmaceuticals in a biosimilar pact

Synthon has entered into a global license agreement with Amgen  and Watson Pharmaceuticals, for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin, which is currently approved for...

Leica Biosystems and Synthon Biopharmaceuticals partner to develop companion diagnostics for cancer

Leica Biosystems and Synthon Biopharmaceuticals, a subsidiary of speciality pharmaceutical company Synthon, have agreed to collaborate on the development and commercialisation of a companion diagnosti...

Watson and Amgen take on Synthon's biosimilar Herceptin

Watson has acquired the licence to Synthon's biosimilar version of Herceptin (trastuzumab) for an undisclosed amount. Watson has in turn contributed the product to its biosimilars collaboration with A...

Synthon chooses Avacta’s Optim 1000 for high throughput formulation studies

Pharmaceutical developers at Synthon have chosen an Optim 1000 high throughput, micro-volume protein analysis system...

Synthon Biopharmaceuticals announces promising results with its antibody-drug conjugate program

Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs).

When Vaccines Go Viral: An Analysis of HPV Vaccine Coverage on YouTube.

This article reports a content analysis of YouTube videos related to the human papillomavirus (HPV) vaccine. In total, 172 YouTube videos were examined with respect to video sources, tones, and viewer...

The metal-carbonylπ(aryl) interaction as a supramolecular synthon for the stabilisation of transition metal carbonyl crystal structures.

M-carbonyl(lone pair)π(aryl) interactions provide stability to their transition metal crystal structures. This supramolecular synthon usually leads to zero- or one-dimensional aggregation patterns; a...

"I'll be your cigarette--Light me up and get on with it": Examining smoking imagery on YouTube.

INTRODUCTION: Smoking imagery on the online video sharing site YouTube is prolific and easily accessed. However, no studies have examined how this content changes across time. We studied the primary m...

Can "YouTube" help students in learning surface anatomy?

AIMS: In a problem-based learning curriculum, most medical students research the Internet for information for their "learning issues." Internet sites such as "YouTube" have becom...

Analysis of eye gaze: Do novice surgeons look at the same location as expert surgeons during a laparoscopic operation?

INTRODUCTION: Eye-gaze technology can be used to track the gaze of surgeons on the surgical monitor. We examine the gaze of surgeons performing a task in the operating room and later watching the oper...